Nice news on the management front:
Scios Board of Directors Elects Donald B. Rice, Ph.D. as Chairman of the Board
November 4, 1998 09:00 AM
MOUNTAIN VIEW, Calif., Nov. 4 /PRNewswire/ -- The board of directors of Scios Inc. SCIO
yesterday unanimously elected Donald B. Rice, Ph.D. (59) as chairman of the board. Dr.
Rice joined the Scios board in September 1997.
Dr. Rice currently serves as president, chief executive officer and founder of UroGenesys,
Inc., a California-based biotechnology company, and is a director of Wells Fargo &
Company and Vulcan Materials Company. He has also served on the boards of Teledyne,
Inc. and Pacific Enterprises.
"We are honored to have such a distinguished individual as Dr. Rice serve as Scios'
chairman," said Richard B. Brewer, president and chief executive officer. "Dr. Rice's
expertise and experience in a variety of industries, including biotechnology, add
tremendous value to the Company. As a non-executive chairman, Dr. Rice will provide key
insights into Scios' future strategies, and I look forward to working closely with him to build
stockholder value."
Dr. Rice served as president and chief operating officer of Teledyne, Inc. from 1993 to
1996, after having served as Secretary of the Air Force, U.S. Department of Defense, from
1989 to 1993. From 1972 to 1989, he headed the RAND Corporation as president and chief
executive officer. From 1970 to 1972, he was assistant director of the Office of
Management and Budget, The White House. From 1967 to 1970, Dr. Rice held the
positions of deputy assistant secretary of defense for resource analysis, and director of
cost analysis for the Department of Defense. From 1965 to 1967, he served to the rank of
captain in the U.S. Army.
Dr. Rice earned a B.S. in Chemical Engineering from the University of Notre Dame, and an
M.S. in Industrial Management and Ph.D. in Economics from Purdue University. He has
served on the National Science board for twelve years and the Defense Science board for
six years. In 1997, he was elected a fellow of the National Academy of Public
Administration. Dr. Rice is also the recipient of the National Humanitarian Award from the
National Conference, and he has been awarded five honorary doctoral degrees.
Scios is a biopharmaceutical company engaged in the discovery, development,
manufacture and commercialization of novel human therapeutics. Scios has two major
clinical development programs. Natrecor(R) (nesiritide) is awaiting approval by the FDA for
the short-term treatment of congestive heart failure after Scios filed an NDA in April 1998.
Fiblast(R) (trafermin) is in Phase II/III clinical trials in Europe for the treatment of stroke and
additional Phase II clinical trials in vascular disease are planned. The Company has
research and development collaborations with Bayer AG, Wyeth-Ayerst Laboratories, the
pharmaceutical division of American Home Products Corporation, Kaken Pharmaceutical
Co., Ltd., Novo Nordisk A/S of Denmark, Eli Lilly and Company, and The DuPont
Pharmaceuticals Company. Scios' commercial operations division markets six psychiatric
products. Additional information on Scios is available at its web site located at
sciosinc.com and in the Company's various filings with the Securities and
Exchange Commission.
Contact: Mary Ann Allencourt of Scios Inc., 650-940-6629.
SOURCE Scios Inc.
|
